Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urinary Tract Calculi I: Introduction01:28

Urinary Tract Calculi I: Introduction

988
Renal calculi, or kidney stones, are solid deposits of minerals and salts formed inside the kidneys. In medical terminology, "calculus" refers to the stone itself, while "lithiasis" describes the process of stone formation. Depending on their location within the urinary system, these stones may be classified as either urolithiasis, when situated within the urinary tract, or nephrolithiasis, when located within the kidneys. Each term signifies the specific impact of the stone.Predisposition...
988
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

360
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
360
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

2.1K
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
2.1K
Renal Tubule and Collecting Duct01:24

Renal Tubule and Collecting Duct

4.7K
The renal tubule is divided into three parts: the proximal convoluted tubule (PCT), the Loop of Henle (LOH), and the distal convoluted tubule (DCT).
Proximal Convoluted Tubule (PCT):
The PCT is the initial segment of the renal tubule, extending from the Bowman's capsule that encloses the glomerulus. Its convoluted structure and microvilli-lined cells increase the surface area for reabsorption. The PCT reabsorbs glucose, amino acids, sodium, and water from the filtrate, ensuring essential...
4.7K
Urinary Tract Calculi IV: Nutrition Therapy and Prevention01:27

Urinary Tract Calculi IV: Nutrition Therapy and Prevention

704
Management of renal calculi focuses on effective strategies like tailored nutrition and hydration therapy. Adjusting diet and fluid intake reduces stone formation and recurrence, making these interventions simple yet powerful in kidney stone prevention and management.Understanding Kidney StonesKidney stones form when calcium, oxalate, uric acid, and cystine concentrate and crystallize in urine. Factors contributing to their formation include genetic predisposition, certain medical conditions,...
704
Renal Corpuscle01:20

Renal Corpuscle

9.7K
The glomerulus and Bowman's capsule are two essential components of the nephron, which is the functional unit of the kidney. These microscopic structures play a critical role in the process of blood filtration to produce urine.
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
9.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Real-world treatment sequencing and survival in ROS1-Rearranged NSCLC across evolving treatment eras: Findings from the AURORA multi-centre registry (AURORA-ROS1).

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Long-term survival outcomes after biomarker-guided thromboprophylaxis in cancer: extended follow-up of the TARGET-TP randomised trial.

Journal of the National Cancer Institute·2026
Same author

Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial.

Nature medicine·2026

Related Experiment Video

Updated: Apr 16, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.4K

Complex renal cysts associated with crizotinib treatment.

Patrick Schnell1, Cynthia H Bartlett1, Benjamin J Solomon2

  • 1Pfizer Oncology, New York, New York.

Cancer Medicine
|March 11, 2015
PubMed
Summary

Crizotinib treatment for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is associated with increased renal cyst development. Monitoring is advised, but dose adjustments are usually not needed, allowing continued patient benefit.

Keywords:
CrizotinibNSCLCindependent radiologic reviewrenal cystsrisk factors

More Related Videos

Author Spotlight: Developing a Bedside Protocol for Kidney and Genitourinary Ultrasonography
03:19

Author Spotlight: Developing a Bedside Protocol for Kidney and Genitourinary Ultrasonography

Published on: June 21, 2024

2.9K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K

Related Experiment Videos

Last Updated: Apr 16, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.4K
Author Spotlight: Developing a Bedside Protocol for Kidney and Genitourinary Ultrasonography
03:19

Author Spotlight: Developing a Bedside Protocol for Kidney and Genitourinary Ultrasonography

Published on: June 21, 2024

2.9K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K

Area of Science:

  • Oncology
  • Pharmacology
  • Radiology

Background:

  • Crizotinib is a targeted therapy for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
  • Clinical trials observed an association between crizotinib and renal cyst development.

Purpose of the Study:

  • To investigate the association between crizotinib treatment and renal cyst development in ALK-positive NSCLC patients.
  • To assess the incidence, characteristics, and risk factors of renal cysts during crizotinib therapy.

Main Methods:

  • Reviewed serious adverse event (SAE) reports of renal cysts from 1375 patients across four clinical trials.
  • Conducted a blinded, retrospective, independent radiologic review (IRR) of scans from 255 crizotinib-treated patients on study for ≥ 6 months.
  • Assessed risk factors, including ethnicity, for renal cyst development.

Main Results:

  • Among 17 patients with renal cysts reported as SAEs, seven showed invasion into adjacent structures without malignancy; most continued crizotinib without dose modification.
  • In the IRR, 22% had preexisting simple cysts, 3% complex cysts, and 2% both.
  • At 6 months, 9% of patients acquired new cysts, and 2% with preexisting cysts experienced new cysts or enlargements; Asians, particularly Koreans, showed a higher risk (OR 5.18).

Conclusions:

  • Crizotinib treatment is associated with an increased risk of renal cyst development and progression in ALK-positive NSCLC patients.
  • Close monitoring for renal cysts is recommended during crizotinib therapy.
  • Dosing modifications were generally not required, enabling continued treatment and clinical benefit for most patients.